Efficacy of Tirzepatide in Patients with Idiopathic Intracranial Hypertension
Author Information
Author(s): Azzam Ahmed Y., Essibayi Muhammed Amir, Farkas Nathan, Azab Mohammed A., Morsy Mahmoud M., Elamin Osman, Elswedy Adam, Zomia Ahmed Saad Al, Alotaibi Hammam A., Alamoud Ahmed, Atallah Oday, Abukhadijah Hana J., Dmytriw Adam A., Baker Amanda, Khatri Deepak, Haranhalli Neil, Altschul David J.
Primary Institution: Albert Einstein College of Medicine
Hypothesis
This study aimed to evaluate tirzepatide’s efficacy as an adjunctive therapy in IIH management.
Conclusion
Tirzepatide provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes.
Supporting Evidence
- Tirzepatide showed a 68% reduction in papilledema risk at 24 months.
- A 73.9% reduction in visual disturbance and blindness risk was observed.
- Headache risk was reduced by 19.7% in the tirzepatide group.
- The tirzepatide group demonstrated significant body-mass index reductions.
- Significant improvements were observed across all measured outcomes.
Takeaway
Tirzepatide helps people with a brain condition called IIH feel better by reducing swelling and improving vision.
Methodology
A retrospective cohort analysis using the TriNetX Global Health Research Network, comparing 193 tirzepatide-exposed IIH patients with 193 controls receiving standard care.
Potential Biases
Potential for selection bias due to the retrospective nature of the study.
Limitations
The retrospective design introduces potential for unmeasured confounders, and the lack of standardized ICP measurements may impact generalizability.
Participant Demographics
Predominantly female population, with a mean age of 37.7 years and a high prevalence of obesity.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 0.189–0.542
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website